Macular Corneal Dystrophy – Molecular Genetics as the Key in Treatment-Refractory Keratopathy

Jan Spindler,Samuel Koller,Urs Graf,Wolfgang Berger,Christina Gerth-Kahlert,Frank Blaser
DOI: https://doi.org/10.1055/a-2219-8288
2024-04-25
Klinische Monatsblätter für Augenheilkunde
Abstract:Macular corneal dystrophy (MCD) is a severe and rare form of corneal dystrophy. It usually develops in childhood or adolescence [1], [2] and is a genetic disorder with an autosomal recessive pattern of inheritance. MCD is characterized by the formation of progressive bilateral scattered gray-white punctuate opacities in the corneal stroma and central corneal thinning. It typically starts centrally, which then progressively extends to the periphery and eventually involves the entire corneal thickness. If left untreated, MCD leads to bilateral deterioration of visual acuity. Currently, the most effective treatment is corneal transplantation [1], [2]. Even though recurrence of MCD is rare, it may occur many decades after penetrating keratoplasty (PKP), which remains the gold standard in the cure of MCD for long-term visual rehabilitation. Received: 11 November 2023 Accepted: 28 November 2023 Article published online: 23 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
ophthalmology
What problem does this paper attempt to address?